It's been a busy few months for Wright Medical (NASDAQ:WMGI).
The company completed its merger with Tornier, creating a new entity
with a strong share in the fast-growing orthopedic extremities
sub-sector. Wright Medical also managed to secure FDA approval for its
long-awaited Augment biological, a product that could be game changer
with multi-hundred million dollar sales potential.
Now comes the harder, and decidedly less glamorous, part - execution. Wright Medical will have to deal with Johnson & Johnson (NYSE:JNJ), Stryker (NYSE:SYK), and Zimmer Biomet (NYSE:ZBH)
on a daily basis, while also integrating the sales forces and ensuring a
smooth transition into a blended entity. The high-single digit market
growth of upper and lower extremities makes this a potentially strong
multi-year growth story, but Wall Street won't be forgiving if the sales
growth and cost synergies don't materialize.
Read more here:
Wright Medical Has To Execute Against A Promising Backdrop
No comments:
Post a Comment